>
pdufa.bio

Seralutinib

Updated ยทnext FDA decision on the calendar

Seralutinib is a Gossamer Bio, Inc. program. Its next catalyst is a Readout in Dec 2026. Every date links its source.

GOSS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Gossamer Bio, Inc. (GOSS). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026GOSSReadout · Dec 2027GOSS

Questions

When is Seralutinib's next FDA decision or readout?

The next tracked catalyst for Seralutinib is a Readout in Dec 2026.

What happened at Seralutinib's most recent FDA decision?

No FDA decision for Seralutinib is in our archive yet.

Who makes Seralutinib?

Gossamer Bio, Inc. (GOSS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.